Mylan Signs Exclusive Agreement with Gilead Sciences to Distribute Sovaldi® and Harvoni® in India

Mylan Inc. (Nasdaq: MYL) today announced that its Indian subsidiary, Mylan Pharmaceuticals Private Limited, has entered into an agreement with Gilead Sciences, under which Mylan has been appointed as the exclusive distributor of Sovaldi® (sofosbuvir 400mg tablets) and Harvoni®(ledipasvir 90mg/sofosbuvir 400 mg tablets) for the treatment of chronic hepatitis C, in India. As Gilead's exclusive branded medicine distribution partner, Mylan expects to begin distribution of Sovaldi in India in Q2 2015. Sovaldi received regulatory approval in India in January 2015 – the first country in Asia to approve the medicine. Read more: bit.ly/1MOTVih

oldestnewest